Showing results (81-90 of 141) with videos related to
Sort By:
Pageof 15
Blood|October 20, 2020
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myelomaJill Corre, Aurore Perrot, Denis Caillot, et al.European Journal of Haematology|February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported OutcomesAurore Perrot, Thierry Facon, Torben Plesner, et al.Bone Marrow Transplantation|May 10, 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMTMeral Beksac, Simona Iacobelli, Linda Koster, et al.Blood|September 3, 2021
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experienceAlexis Caulier, Murielle Roussel, Pierre Morel, et al.Leukemia|January 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA studyPhilippe Moreau, Thierry Facon, Saad Z Usmani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
The translocation t(4;14) can be present only in minor subclones in multiple myelomaBenjamin Hébraud, Denis Caillot, Jill Corre, et al.Leukemia & Lymphoma|July 13, 2017
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteriaGuillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, et al.Blood|January 16, 2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02Xavier Leleu, Michel Attal, Bertrand Arnulf, et al.The New England Journal of Medicine|April 6, 2017
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaMichel Attal, Valerie Lauwers-Cances, Cyrille Hulin, et al.Pageof 15